FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2903139826> ?p ?o ?g. }

• W2903139826 endingPage "248" @default.
• W2903139826 startingPage "240" @default.
• W2903139826 abstract "ObjectivesTo assess the safety and efficacy of four vilaprisan doses (0.5–4.0 mg) in women with uterine fibroids.DesignRandomized, double-blind, placebo-controlled, multicenter trial.SettingNinety-eight centers in 12 countries.Patient(s)Women aged 18–50 years with uterine fibroids and heavy menstrual bleeding were randomized equally to oral vilaprisan at 0.5, 1.0, 2.0, or 4.0 mg or placebo once daily.Intervention(s)Treatment for 12 weeks, 24-week follow-up.Main Outcome Measure(s)Primary end point was absence of scheduled or unscheduled bleeding/spotting. Key secondary efficacy end points included volume of menstrual blood loss and change in fibroid volume.Result(s)A total of 309 patients were randomized, and 300 received treatment. Complete absence of bleeding/spotting was observed in 30%, 56%, 54%, and 60% of patients in the vilaprisan 0.5, 1.0, 2.0, and 4.0 mg groups, respectively, versus 1.7% with placebo. After 12 weeks, >83% of women achieved amenorrhea (<2 mL/28 days) with ≥1.0 mg vilaprisan versus 9% with placebo. Heavy menstrual bleeding stopped (but returned at a lower volume after treatment cessation) with ≥1.0 mg vilaprisan treatment. Reductions in fibroid volume of up to 41% were observed. Most patients receiving vilaprisan reported improvements in symptom severity. No safety concerns were identified in general safety, endometrial safety (by biopsy), laboratory values, and ultrasound examinations.Conclusion(s)ASTEROID 1 supports the efficacy of vilaprisan for the treatment of heavy menstrual bleeding associated with uterine fibroids. Daily oral treatment with vilaprisan 0.5–4.0 mg was well tolerated, and vilaprisan 2.0 mg once daily has been selected for further investigation.Clinical Trial Registration NumberNCT02131662. To assess the safety and efficacy of four vilaprisan doses (0.5–4.0 mg) in women with uterine fibroids. Randomized, double-blind, placebo-controlled, multicenter trial. Ninety-eight centers in 12 countries. Women aged 18–50 years with uterine fibroids and heavy menstrual bleeding were randomized equally to oral vilaprisan at 0.5, 1.0, 2.0, or 4.0 mg or placebo once daily. Treatment for 12 weeks, 24-week follow-up. Primary end point was absence of scheduled or unscheduled bleeding/spotting. Key secondary efficacy end points included volume of menstrual blood loss and change in fibroid volume. A total of 309 patients were randomized, and 300 received treatment. Complete absence of bleeding/spotting was observed in 30%, 56%, 54%, and 60% of patients in the vilaprisan 0.5, 1.0, 2.0, and 4.0 mg groups, respectively, versus 1.7% with placebo. After 12 weeks, >83% of women achieved amenorrhea (<2 mL/28 days) with ≥1.0 mg vilaprisan versus 9% with placebo. Heavy menstrual bleeding stopped (but returned at a lower volume after treatment cessation) with ≥1.0 mg vilaprisan treatment. Reductions in fibroid volume of up to 41% were observed. Most patients receiving vilaprisan reported improvements in symptom severity. No safety concerns were identified in general safety, endometrial safety (by biopsy), laboratory values, and ultrasound examinations. ASTEROID 1 supports the efficacy of vilaprisan for the treatment of heavy menstrual bleeding associated with uterine fibroids. Daily oral treatment with vilaprisan 0.5–4.0 mg was well tolerated, and vilaprisan 2.0 mg once daily has been selected for further investigation." @default.
• W2903139826 created "2018-12-11" @default.
• W2903139826 creator A5000822230 @default.
• W2903139826 creator A5017616696 @default.
• W2903139826 creator A5021933390 @default.
• W2903139826 creator A5055891816 @default.
• W2903139826 creator A5058749241 @default.
• W2903139826 creator A5079180373 @default.
• W2903139826 creator A5082633299 @default.
• W2903139826 creator A5083344849 @default.
• W2903139826 creator A5088504387 @default.
• W2903139826 date "2019-02-01" @default.
• W2903139826 modified "2023-09-30" @default.
• W2903139826 title "Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study" @default.
• W2903139826 cites W1560058331 @default.
• W2903139826 cites W1827097019 @default.
• W2903139826 cites W1969018878 @default.
• W2903139826 cites W1969068003 @default.
• W2903139826 cites W1973438143 @default.
• W2903139826 cites W1996100965 @default.
• W2903139826 cites W1997724693 @default.
• W2903139826 cites W1998329793 @default.
• W2903139826 cites W2012880254 @default.
• W2903139826 cites W2021171884 @default.
• W2903139826 cites W2022079794 @default.
• W2903139826 cites W2026392453 @default.
• W2903139826 cites W2044548776 @default.
• W2903139826 cites W2071333781 @default.
• W2903139826 cites W2080980290 @default.
• W2903139826 cites W2085848166 @default.
• W2903139826 cites W2095908642 @default.
• W2903139826 cites W2097851570 @default.
• W2903139826 cites W2106587450 @default.
• W2903139826 cites W2107830002 @default.
• W2903139826 cites W2156957181 @default.
• W2903139826 cites W2169959327 @default.
• W2903139826 cites W2280615486 @default.
• W2903139826 cites W2300322306 @default.
• W2903139826 cites W2314930650 @default.
• W2903139826 cites W2411141066 @default.
• W2903139826 cites W2496662864 @default.
• W2903139826 cites W2568464606 @default.
• W2903139826 cites W2586561409 @default.
• W2903139826 cites W2595206985 @default.
• W2903139826 cites W2602082991 @default.
• W2903139826 cites W2783095880 @default.
• W2903139826 cites W3194956376 @default.
• W2903139826 doi "https://doi.org/10.1016/j.fertnstert.2018.10.012" @default.
• W2903139826 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30527839" @default.
• W2903139826 hasPublicationYear "2019" @default.
• W2903139826 type Work @default.
• W2903139826 sameAs 2903139826 @default.
• W2903139826 citedByCount "23" @default.
• W2903139826 countsByYear W29031398262019 @default.
• W2903139826 countsByYear W29031398262020 @default.
• W2903139826 countsByYear W29031398262021 @default.
• W2903139826 countsByYear W29031398262022 @default.
• W2903139826 countsByYear W29031398262023 @default.
• W2903139826 crossrefType "journal-article" @default.
• W2903139826 hasAuthorship W2903139826A5000822230 @default.
• W2903139826 hasAuthorship W2903139826A5017616696 @default.
• W2903139826 hasAuthorship W2903139826A5021933390 @default.
• W2903139826 hasAuthorship W2903139826A5055891816 @default.
• W2903139826 hasAuthorship W2903139826A5058749241 @default.
• W2903139826 hasAuthorship W2903139826A5079180373 @default.
• W2903139826 hasAuthorship W2903139826A5082633299 @default.
• W2903139826 hasAuthorship W2903139826A5083344849 @default.
• W2903139826 hasAuthorship W2903139826A5088504387 @default.
• W2903139826 hasBestOaLocation W29031398261 @default.
• W2903139826 hasConcept C126322002 @default.
• W2903139826 hasConcept C141071460 @default.
• W2903139826 hasConcept C142724271 @default.
• W2903139826 hasConcept C168563851 @default.
• W2903139826 hasConcept C204787440 @default.
• W2903139826 hasConcept C27081682 @default.
• W2903139826 hasConcept C2778058571 @default.
• W2903139826 hasConcept C2779234561 @default.
• W2903139826 hasConcept C2779771394 @default.
• W2903139826 hasConcept C2780566971 @default.
• W2903139826 hasConcept C29456083 @default.
• W2903139826 hasConcept C54355233 @default.
• W2903139826 hasConcept C71924100 @default.
• W2903139826 hasConcept C86803240 @default.
• W2903139826 hasConceptScore W2903139826C126322002 @default.
• W2903139826 hasConceptScore W2903139826C141071460 @default.
• W2903139826 hasConceptScore W2903139826C142724271 @default.
• W2903139826 hasConceptScore W2903139826C168563851 @default.
• W2903139826 hasConceptScore W2903139826C204787440 @default.
• W2903139826 hasConceptScore W2903139826C27081682 @default.
• W2903139826 hasConceptScore W2903139826C2778058571 @default.
• W2903139826 hasConceptScore W2903139826C2779234561 @default.
• W2903139826 hasConceptScore W2903139826C2779771394 @default.
• W2903139826 hasConceptScore W2903139826C2780566971 @default.
• W2903139826 hasConceptScore W2903139826C29456083 @default.
• W2903139826 hasConceptScore W2903139826C54355233 @default.
• W2903139826 hasConceptScore W2903139826C71924100 @default.
• W2903139826 hasConceptScore W2903139826C86803240 @default.
• W2903139826 hasFunder F4320307105 @default.

• next